Curis Inc
CUS0
Company Profile
Business description
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Contact
128 Spring Street
Building C - Suite 500
LexingtonMA02421
USAT: +1 617 503-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
49
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,552.60 | 71.00 | 0.84% |
CAC 40 | 7,338.67 | 86.93 | -1.17% |
DAX 40 | 19,215.48 | 147.04 | -0.76% |
Dow JONES (US) | 43,988.99 | 259.65 | 0.59% |
FTSE 100 | 8,072.39 | 68.35 | -0.84% |
HKSE | 20,728.19 | 225.15 | -1.07% |
NASDAQ | 19,286.78 | 17.32 | 0.09% |
Nikkei 225 | 39,500.37 | 118.96 | 0.30% |
NZX 50 Index | 12,770.33 | 188.95 | 1.50% |
S&P 500 | 5,995.54 | 22.44 | 0.38% |
S&P/ASX 200 | 8,295.10 | 68.80 | 0.84% |
SSE Composite Index | 3,452.30 | 18.36 | -0.53% |